Curaleaf products display at Curaleaf store in Queens in New York, U.S., on Thursday, Oct.18, 2018. (Photo: Jeenah Moon/Bloomberg) Curaleaf products display at Curaleaf store in Queens in New York, U.S., on Thursday, Oct.18, 2018. (Photo: Jeenah Moon/Bloomberg)

Federal regulators last Tuesday threatened cannabis giant Curaleaf with possible legal action for allegedly making unsubstantiated medical claims about the cannabidiol, or CBD, products on its website and on social media.

Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader

Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Mike Scarcella

Mike Scarcella is a senior editor in Washington on ALM Media's regulatory desk. Contact him at [email protected]. On Twitter: @MikeScarcella. Mike works on a slate of newsletters: Supreme Court Brief | Higher Law | Compliance Hot Spots | Labor of Law.